title: Experimental antitumour activity of S 16020-2 in a panel of human tumours.
abstract: The antitumour activity of S 16020-2, a new topoisomerase II inhibitor, was evaluated in comparison with doxorubicin against 13 human tumours, including colon (HT-29, Colo320DM), breast (MCF7, MDAMB-231), ovary (SK-OV-3, A2780, NIH:OVCAR-3), non-small cell lung (NCI-H460, A549, Calu-6, NCI-H125) and small-cell lung (NCI-H69, SCLC6) cancers. S 16020-2 was administered weekly intravenous within a dose range of 20-90 mg/kg for 3 weeks. Antitumour responses were obtained in all the tumour types tested except in the two colon cancers. S 16020-2 produced significant growth delays in nine tumour models and induced regressions of all A549 lung tumours. The antitumour activity of S 16020-2 was superior to that of doxorubicin against the NCI-H460, A549, NCI-H69, SCLC6 and NIH:OVCAR-3 xenografts. These results demonstrate the broad spectrum of antitumour activity of S 16020-2 in a large panel of in vivo experimental models and confirm its interest as a potential agent in the treatment of malignant disease.
authors.affiliation: Institut de Recherches Servier, Division de Cancérologie expérimentale, Suresnes, France.
authors.forename: L
authors.initials: L
authors.lastname: Kraus-Berthier
authors.forename: N
authors.initials: N
authors.lastname: Guilbaud
authors.forename: M
authors.initials: M
authors.lastname: Jan
authors.forename: D
authors.initials: D
authors.lastname: Saint-Dizier
authors.forename: M H
authors.initials: MH
authors.lastname: Rouillon
authors.forename: M F
authors.initials: MF
authors.lastname: Burbridge
authors.forename: A
authors.initials: A
authors.lastname: Pierré
authors.forename: G
authors.initials: G
authors.lastname: Atassi
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D004611:Ellipticines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000188:drug therapy; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004611:Ellipticines; C101591:S 16020-2; D004317:Doxorubicin